Phase 3 N=33 Usability of an AI for M923 in Subjects With Moderate to Severe RA
Rheumatoid Arthritis
Primary: Usability of the Auto-injector (AI) at Week 4 — 8.15; 8.17; 9.27; 8.12 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Antiphospholipid Syndrome
Primary: Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients — 31.2; 12.2; 0.4; 2.7 pg/mL
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Phase 3 N=720 Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge
Analgesia After ED Discharge for Extremity Injuries
Primary: Difference in Pain Intensity Score Before and After Last Dose. — 7.6; 7.6; 7.9; 7.9 units on a scale
N/A N=40 Platelet-rich Fibrin and Connective Tissue Graft in Recession Treatment
Gingival Recession
Primary: Vertical Recession — 3.35; 3.20; 0.38; 0.65 mm — p=0.259
Phase 2 N=107 Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Adenomatous Polyp
Primary: Adenoma Recurrence Rate for the Treatment Arm Relative to Placebo — 0.595; 0.581 proportion of participants — p=0.448
Phase 3 N=734 Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
Human Immunodeficiency Virus (HIV)
Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 — 84.3; 80.8 Percentage of Participants
N/A N=155 EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1
Eye-tracking
Primary: Changes in the Eye-tracking Score Before and After Practice or Game: Phase Error — -0.6; -0.8 Degrees
Phase 2 N=131 Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Metastatic Breast Cancer
Primary: Progression-free Survival — 10.3; 5.1 months — p=0.02
Phase 2 N=38 N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
Bipolar Disorder
Primary: Number of Patients Demonstrating a > 50% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) — 3; 2; 5; 6 Participants
N/A N=12 The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study
Chronic Schizophrenia
Primary: Cognition on the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) Scale — 7; 5.25; -1.5; -1.33 units on a scale
Phase 3 N=86 OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 — 2.04; 2.31 units on a scale
N/A N=11 Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
Imaging of the Brain and Antipsychotics · Neuronal Network Changes
Primary: Repeatable Battery for the Assessment of Neuropsychological Status — -1.5; -0.5 RBANS T-Scale point difference
Phase 3 N=673 Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Number of Participants Who Did Not Experience a Flare During Period 2 by Week 68 — 72; 107 Participants — p=<0.001
Phase 2 N=12 Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Number of Subjects Who Died — 0; 0; 0; 0 Participants